ClinicalTrials.gg
RecruitingNCT07176507MULTIVALVEUpdated Jun 12, 2026

MULTIVALVE : A Prospective Multicentre Study of Multiple and Mixed Valvular Heart Disease

An observational study in Valvular Heart Disease, sponsored by French Cardiology Society. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by French Cardiology Society · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Heart Valve Diseases with a site in France — 16 open to participants now, 22 under way, 1 of them phase 3. Heart Valve Diseases · France.

Planned enrollment
8th of 17
1,000 · median 800
Started
2025
with 2 others
Observational
17 of 48
10 open now
Primary completion
2028-10
later than 15 of 21 live
Registered
47th of 48
by date

Among the 48 studies in Heart Valve Diseases with a site in France, this one is the 8th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2025, is one of 17 observational ones, reaches primary completion later than 15 of the 21 other live ones, and was the 47th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

16 of the 48 studies in Heart Valve Diseases with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Heart Valve Diseases with a site in France, or all of them as a file.
02

Study summary

Multiple and mixed valvular heart disease (MMVD) is a common condition in clinical practice. It corresponds to a combination of stenotic or leaky lesions on two or more heart valves (multiple valve disease), or a combination of stenotic and leaky lesions on the same valve (mixed valve disease). However, the management of their clinical, biological and cardiovascular imaging is not well established. Current European Society of Cardiology (ESC) recommendations primarily address the various valve diseases in isolation. This results in an absence of reliable recommendations for managing MMVD, with different approaches being adopted by care centres.

In order to address this knowledge gap regarding MMVD, it is crucial to assess its prevalence, the cardiovascular imaging methods employed and the management strategies, as well as to identify prognostic factors for the various combinations of valve disease.

The multicentre MMVD study will be a valuable resource as it will improve our understanding of the prognosis for patients with MMVD. It will highlight imaging and biological markers associated with the prognosis of different combinations of MMVD.

Read the detailed description

National, Prospective, Multicentric Registry. Patients with a diagnosis of MMVD identified by echocardiography will be included and followed up at 1, 2, 3, 4 and 5 years.

03

Conditions studied

  • Valvular Heart Disease

Browse trials for

Keywords

  • valvular heart disease
  • Multiple and mixed valvular heart disease
  • multiple valve disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with a diagnosis of MMVD based on cardiovascular imaging and defined as follows:

At least two cases of moderate to severe valvular heart disease, as assessed by a cardiologist and defined by transthoracic echocardiography (TTE) on one or more valves. This is in line with the recommendations of the European Society of Cardiology (ESC), the American Society of Echocardiography (ASE) and expert opinion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • The patient has been informed of the study and has not refused to participate.
  • An echocardiographic diagnosis of MMVD is defined as having at least two moderate to severe valvulopathies, as assessed by a cardiologist using transthoracic echocardiography (TTE), on one or more valves. This is in line with the recommendations of the ESC, the ASE, and expert opinion.

Exclusion criteria

Exclusion Criteria:

  • History of valve surgery or percutaneous valve intervention involving the valve in question.
  • A history of infective endocarditis, whether treated surgically or not, confirmed according to the modified Duke criteria.
  • Acute infective endocarditis at the time of evaluation for inclusion, confirmed according to the modified Duke criteria.
  • Complex congenital heart disease.
  • Patients who are already included in the European EACVI-MMVD study.
  • Pregnant women
  • Patients not affiliated to social security
  • Patients who are minors
  • Patients under guardianship, curatorship or judicial supervision
  • Patients who refuse to participate in this register.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with a diagnosis of MMVD

    Patients with a diagnosis of MMVD based on cardiovascular imaging and defined as follows: At least two cases of moderate to severe valvular heart disease, as assessed by a cardiologist and defined by transthoracic echocardiography (TTE) on one or more valves. This is in line with the recommendations of the European Society of Cardiology (ESC), the American Society of Echocardiography (ASE) and expert opinion.

06

What researchers measure

Primary outcomes

  1. To assess the association between cardiovascular imaging parameters (echocardiography and cardiac MRI) and cardiovascular event-free survival in a population of MMVD.

    Survival without cardiovascular event

    Time frame: 1 year after inclusion

Secondary outcomes

  1. To assess the association between cardiovascular imaging parameters and survival

    Time frame: at 1, 2, 3, 4 and 5 years after inclusion

  2. Proportion of patients who did not experience a cardiovascular event

    Time frame: at 1, 2, 3, 4 and 5 years after inclusion

  3. Proportion of patients who are alive

    Time frame: at 1, 2, 3, 4 and 5 years after inclusion

  4. Proportion of patients who did not experience a cardiovascular event depending on the type of treatment (medical, surgical or percutaneous)

    Time frame: at 1, 2, 3, 4 and 5 years after inclusion

  5. Proportion of patients who are alive depending on the type of treatment (medical, surgical or percutaneous)

    Time frame: at 1, 2, 3, 4 and 5 years after inclusion

  6. To assess the progression of the stage of severity of valvulopathy

    Echocardiography

    Time frame: at 1, 2, 3, 4 and 5 years after inclusion

  7. % of patients with MMVD combinations

    Time frame: during 5 years after inclusion

  8. Measurement of cardiovascular biomarkers

    BNP or NT-pro-BNP and troponin

    Time frame: at baseline and 1, 2, 3, 4 and 5 years after inclusion

  9. Assessing the association between cardiovascular biomarkers in patients with MMVD and survival

    BNP or NT-pro-BNP and troponin, vital status

    Time frame: during 5 years after inclusion

  10. Assessing the association between cardiovascular biomarkers in patients with MMVD and cardiovascular event-free survival

    BNP or NT-pro-BNP and troponin, Survival without cardiovascular event

    Time frame: during 5 years after inclusion

  11. Exploring the value of cardiovascular biomarkers analysed in a centralised laboratory (optional)

    Biobank (optional)

    Time frame: at baseline

07

Study locations

2 of 2 sites recruiting
  • Chu Lille- Hopital Cardiologique
    Lille, France
    Recruiting
  • Chu Lariboisiere (Aphp)
    Paris, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 36 months after the start.

Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 36 months is below that.

Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Sep 16, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2032
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07176507
Lead sponsor
French Cardiology Society
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Oct 30, 2025
Primary completion
Oct 2028 (estimated)
Completion
Oct 2032 (estimated)
Last update
Jun 12, 2026

Study contacts

Théo PEZEL
Contact
multivalve@sfcardio.fr
01 44 90 70 28 ext. +33
Augustin COISNE
Contact
multivalve@sfcardio.fr
01 44 90 70 28 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion